246pa Meta-analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-blocking Anti-erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers.

G. Macbeath1, B. Adiwijaya1, J. Liu2, L.V. Sequist3, E. Pujade-Lauraine5, M. Higgins3, I. Tabah-Fisch5, J. Pearlberg6, V. Moyo7, W. Kubasek1, R. Nering8, A. Czibere8 Translational Research and Discovery, Merrimack Pharmaceuticals, Cambridge, MA, USA Gynecologic Oncology Program, Dana Farber Cancer Institute, Boston, MA, USA Hematology/oncology, Massachusetts General Hospital, Boston, MA, USA CHU Paris Centre Hôpital Hôtel-dieu, CHU Paris Centre Hôpital Hôtel-Dieu, Paris, FRANCE Sanofi Oncology, Sanofi, Paris, FRANCE Sanofi Oncology, Sanofi, Cambridge, MA, USA Discovery, Merrimack Pharmaceuticals, Cambridge, MA, USA Clinical Development, Merrimack Pharmaceuticals, Cambridge, MA, USA